Search The Medical Knowledge Base

Drug Details

BAXAN

• Drug Class Description
  Cephalosporins.
• Generic Name
  Cefadroxil
• Presentation
  Capsule. Oral suspension.
• Description
  Baxan Capsules: contain Cefadroxil Monohydrate equivalent to 500mg cefadroxil activity. Baxan Suspension: contains Cefadroxil Monohydrate equivalent to 125mg, 250mg or 500mg cefadroxil activity per 5ml.
• Indications
  Baxan is indicated in the treatment of the following infections when due to susceptible micro-organisms: Respiratory tract infections: Tonsillitis, pharyngitis, lobar and bronchopneumonia, acute and chronic bronchitis, pulmonary abscess, empyema, pleurisy, sinusitis, laryngitis, otitis media. Skin and soft-tissue infections: Lymphadenitis, abscesses, cellulitis, decubitus ulcers, mastitis, furunculosis, erysipelas. Genitourinary tract infections: Pyelonephritis, cystitis, urethritis, gynaecological infections. Other infections: Osteomyelitis, septic arthritis.
• Adult Dosage
  

  The bioavailability and consequent chemotherapeutic effects of cefadroxil are unaffected by food. It may, therefore, be taken with meals or on an empty stomach.

  Adults and Children Weighing More Than 40kg (88lbs):

  500mg to 1g twice a day, depending upon the severity of infection.

  Alternatively, in skin and soft tissue and uncomplicated urinary tract infections, 1g once a day.

  In the treatment of beta-haemolytic streptococcal infections, Baxan should be administered for at least 10 days.
  
  Renal Impairment:

  In patients with renal impairment, the dosage should be adjusted according to creatinine clearance rates to prevent drug accumulation and serum levels should be monitored.

  A modified dosage schedule is unnecessary in patients with creatinine clearance rates of greater than 50ml/min. In those patients with creatinine clearance rates of 50ml/min or less, the following dosage schedule is recommended as a guideline, based upon the creatinine clearance rate (ml/min: 1.73 m²).

  Patients with renal insufficiency may be treated with an initial dose of 500mg to 1000mg of Baxan. Subsequent doses may be administered according to the following table:

  Creatinine Clearance	Dose	Dose Interval
  0 - 10 ml/min / 1.73 m²	500 - 1000 mg	36 hrs
  11 - 25 ml/min / 1.73 m²	500 - 1000 mg	24 hrs
  26 - 50 ml/min / 1.73 m²	500 - 1000 mg	12 hrs

  Baxan can be removed from the body by haemodialysis.

• Child Dosage
  

  Children Weighing Less Than 40kg (88lbs):

  Under 1 Year:
  25mg/kg daily in divided doses, e.g. 2.5ml of the 125mg per 5ml suspension twice a day for a 6 month old infant weighing 5kg, or 5ml of the 125ml per 5ml suspension twice a day for a 1 year old infant weighing 10kg.
   
  1-6 years:
  250mg twice a day.
   
  Over 6 years:
  500mg twice a day.
   

   

• Elderly Dosage
  

  No specific dosage recommendations or precautions for use in the elderly except to monitor those patients with impaired renal function.

  The bioavailability and consequent chemotherapeutic effects of cefadroxil are unaffected by food. It may, therefore, be taken with meals or on an empty stomach.

• Contra Indications
  

  Baxan is contra-indicated in patients with a history of hypersensitivity to any of the ingredients.

• Special Precautions
  

  In patients with a history of penicillin allergy, Baxan should be used with caution. There is evidence of partial cross-allergenicity between the penicillins and the cephalosporins. Should an allergic reaction to Baxan occur, the drug should be discontinued and the patient treated with the usual agents (pressor amines, corticosteroids and/or antihistamines), depending on the severity of the reaction.

  As experience in premature infants and neonates is limited, the use of Baxan in these patients should only be undertaken with caution.

  As with all antibiotics, prolonged use may result in overgrowth of non-susceptible organisms.

  As with other broad spectrum antibiotics, pseudomembranous colitis has been reported. It is important to consider its diagnosis in patients who develop diarrhoea in association with Baxan therapy.

• Interactions
  

  There are not sufficient data available to indicate whether the concurrent use of Baxan and potential nephrotoxic agents such as aminoglycosides causes any alteration in their nephrotoxic effects.

  A false-positive Coombs' reaction may occur in some patients receiving Baxan.

  Urine from patients treated with Baxan may give a false-positive glycosuria reaction when tested with Benedict's or Fehling's solutions. This does not occur with enzyme based tests.

• Adverse Drug Reactions
  

  The most commonly reported side-effects are gastrointestinal disturbances and hypersensitivity phenomena. Rash, pruritus, urticaria, angioneurotic oedema have been observed infrequently. Serum sickness, erythema multiforme and anaphylaxis have been reported rarely. Side-effects, including nausea, vomiting, diarrhoea, dyspepsia, abdominal discomfort, fever, dizziness, headache, arthralgia and genital moniliasis may also occur. Reversible neutropenia may occur rarely, as may leucopenia, thrombocytopenia, agranulocytosis and minor elevations in serum transaminase and Stevens-Johnson syndrome. Colitis, including rare instances of pseudo-membraneous colitis, has been reported.